Clinical trials: Ionizing Radiation Exposure
Ionizing Radiation Exposure
Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
The objective of the study is to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects exposed to ionizing radiation and who are at risk of developing HS-ARS.
- Trial name
- HS-ARS (NCT03797040)
- Testing
- Cell therapy
- Volunteers
- 27 people
- Sponsor
- Pluristem Ltd.